A Phase 1/2 Multi-Center, Safety and Efficacy Study Evaluating Intravenously Administered 131I-TM601 in Patients With Progressive and/or Recurrent Malignant Glioma.

Trial Profile

A Phase 1/2 Multi-Center, Safety and Efficacy Study Evaluating Intravenously Administered 131I-TM601 in Patients With Progressive and/or Recurrent Malignant Glioma.

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 15 Dec 2016

At a glance

  • Drugs TM 601 I-131 (Primary)
  • Indications Glioma
  • Focus Therapeutic Use
  • Sponsors TransMolecular
  • Most Recent Events

    • 22 Jul 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 30 Sep 2008 New source of information identified (Transmolecular media release).
    • 30 Sep 2008 TM 601 I-131 dosing initiated according to a Transmolecular media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top